LPV/r

Phase 3Small molecule

Gilead

LPV/r is one of 9 small molecule programs targeting Tenofovir. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TenofovirActive, not recruiting

TenofovirPhase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Tenofovir

#DrugCompanyPhaseTrials

Tybost

Gilead

Phase 3

6 2

B/F/TAF

Gilead

Phase 3

2 3

ISL/LEN

Gilead

Phase 3

1 4

PTM SEMA

Gilead

Phase 3

1 5

F/TAF

Gilead

Phase 3

1 6

Cobicistat TOS

Gilead

Phase 3

1 7

Third Agent

Gilead

Phase 3

2 8

LPV/r

Gilead

Phase 3

1 9

Truvada

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Active, not recruiting

Tenofovir

NCT02016924

Clinical

Trials by Indication[1]

Monotherapy2 trials

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy

Unknown status·IIRCCS San Raffaele·Phase 3·NCT00437476·60 enrolled

Lopinavir/Ritonavir Monotherapy in Children

Completed·TThe HIV Netherlands Australia Thailand Research Collaboration·Phase 4·NCT00626301·40 enrolled

Atrophy1 trial

Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients

Completed·JJuan A. Arnaiz·Phase 4·NCT00978237·20 enrolled

Tics1 trial

Kaletra Sex/Gender Pharmacokinetics (PK) Study

Completed·EEmory University·Phase 4·NCT00148759·23 enrolled

Hepatitis C1 trial

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy

Unknown status·IIRCCS San Raffaele·Phase 3·NCT00437684·50 enrolled

Second-line Therapy1 trial

Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens

Completed·TThe HIV Netherlands Australia Thailand Research Collaboration·Phase 4·NCT00627055·200 enrolled

3 more indications

Tuberculosis1 trial

Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy

Completed·TThe HIV Netherlands Australia Thailand Research Collaboration·Phase 2·NCT01138202·40 enrolled

Tenofovir1 trial

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Active, not recruiting· Gilead logo

Gilead·Phase 2/3·NCT02016924·133 enrolled

Clinical Trial1 trial

Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial

Completed·—·Phase 4·NCT02431975·73 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for LPV/r. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LPV/r compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LPV/r. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Gilead

LPV/r

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Monotherapy2 trials

Atrophy1 trial

Tics1 trial

Hepatitis C1 trial

Second-line Therapy1 trial

Tuberculosis1 trial

Tenofovir1 trial

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News